⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AMRX News
Amneal Pharmaceuticals, Inc. Class A Common Stock
Dermatomyositis Industry Intelligence Report 2025-2035 - Expanding Therapeutic Innovations and Healthcare Investments in Emerging Markets Driving Industry Growth
globenewswire.com
AMRX
RO
ENDP
HIK
JUB
MLK
Amneal Receives U.S. FDA Approval for Iohexol Injection
globenewswire.com
AMRX
Amneal Reports Third Quarter 2025 Financial Results
globenewswire.com
AMRX
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
globenewswire.com
AMRX
Amneal Launches Brekiya® – the First and Only DHE Autoinjector for Adults with Migraine With or Without Aura and Cluster Headaches
globenewswire.com
AMRX
Amneal to Report Third Quarter 2025 Results on October 30, 2025
globenewswire.com
AMRX
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
globenewswire.com
AMRX